Peijuan Zhu - Search Results

Year	Number of Results
2004	1
2006	2
2008	1
2009	6
2011	3
2012	3
2013	1
2017	2
2018	2
2019	1
2020	2
2021	5
2022	5
2023	2
2024	0

1

Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii.

Zhang J, Song C, Wu M, Yue J, Zhu S, Zhu P, Oo C, Schlender JF, Lv Z, Zhu Y, Sy SKB, Yu M. Zhang J, et al. Among authors: zhu p. Eur J Pharm Sci. 2023 Jun 1;185:106443. doi: 10.1016/j.ejps.2023.106443. Epub 2023 Apr 10. Eur J Pharm Sci. 2023. PMID: 37044198 Free article.

2

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.

Martins FS, Zhu P, Heinrichs MT, Sy SKB. Martins FS, et al. Among authors: zhu p. Br J Clin Pharmacol. 2021 Mar;87(3):1012-1023. doi: 10.1111/bcp.14456. Epub 2020 Jul 24. Br J Clin Pharmacol. 2021. PMID: 32638408 Free article.

3

Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.

Luo MM, Zhu PP, Nnane I, Xiong Y, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Weiss BM, Tran N, Qin X, Vermeulen J, Sharma A, Sun YN, Zhou H. Luo MM, et al. Among authors: zhu pp. J Clin Pharmacol. 2022 May;62(5):656-669. doi: 10.1002/jcph.1994. Epub 2021 Nov 28. J Clin Pharmacol. 2022. PMID: 34708423

4

Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.

Zhu S, Zhang J, Lv Z, Zhu P, Oo C, Yu M, Sy SKB. Zhu S, et al. Among authors: zhu p. Clin Pharmacokinet. 2022 Oct;61(10):1427-1441. doi: 10.1007/s40262-022-01161-y. Epub 2022 Aug 10. Clin Pharmacokinet. 2022. PMID: 35947360

5

Multi-Scenario Simulation of Land Use and Landscape Ecological Risk Response Based on Planning Control.

Wang N, Zhu P, Zhou G, Xing X, Zhang Y. Wang N, et al. Among authors: zhu p. Int J Environ Res Public Health. 2022 Nov 1;19(21):14289. doi: 10.3390/ijerph192114289. Int J Environ Res Public Health. 2022. PMID: 36361163 Free PMC article.

6

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.

Zhu P, Willmann S, Zhou W, Yang H, Michelson AD, McCrindle BW, Li JS, Harris KC, Pina LM, Weber T, Nessel K, Lesko LJ, Kubitza D, Zannikos P. Zhu P, et al. J Clin Pharmacol. 2022 Feb;62(2):220-231. doi: 10.1002/jcph.1966. Epub 2022 Jan 9. J Clin Pharmacol. 2022. PMID: 34524700 Free PMC article. Clinical Trial.

7

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii.

Zhang J, Diao S, Liu Y, Wang H, Liu Y, Zhu S, Feng K, Tang X, Oo C, Zhu P, Lv Z, Yu M, Sy SKB, Zhu Y. Zhang J, et al. Among authors: zhu p. Front Microbiol. 2022 Nov 22;13:1024702. doi: 10.3389/fmicb.2022.1024702. eCollection 2022. Front Microbiol. 2022. PMID: 36483204 Free PMC article.

8

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions.

Willmann S, Coboeken K, Zhang Y, Mayer H, Ince I, Mesic E, Thelen K, Kubitza D, Lensing AWA, Yang H, Zhu P, Mück W, Drenth HJ, Lippert J. Willmann S, et al. Among authors: zhu p. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1195-1207. doi: 10.1002/psp4.12688. Epub 2021 Aug 23. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34292671 Free PMC article.

9

Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy.

Fedrigo NH, Shinohara DR, Mazucheli J, Nishiyama SAB, Carrara-Marroni FE, Martins FS, Zhu P, Yu M, Sy SKB, Tognim MCB. Fedrigo NH, et al. Among authors: zhu p. Sci Rep. 2021 May 31;11(1):11339. doi: 10.1038/s41598-021-90709-2. Sci Rep. 2021. PMID: 34059725 Free PMC article.

10

Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases.

Feng K, Jia N, Zhu P, Sy S, Liu Y, Dong D, Zhu S, Zhang J, Liu Y, Martins FS, Gong H, Lv Z, Yu M, Sy SKB, Zhu Y. Feng K, et al. Among authors: zhu p. J Antimicrob Chemother. 2021 Oct 11;76(11):2875-2883. doi: 10.1093/jac/dkab292. J Antimicrob Chemother. 2021. PMID: 34383928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

33 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year